HOME >> MEDICINE >> NEWS
Three months is too soon to judge a CML patient's response to Gleevec, researchers find

SAN DIEGO, Calif. -- Gleevec has been shown to wipe out leukemia cells in 75 percent of the chronic myeloid leukemia (CML) patients who are treated with it. What oncologists haven't known is how long patients should take Gleevec before its effectiveness can be gauged. A new study to be presented at the American Society of Hematology (ASH) 45th Annual Meeting on Monday, Dec. 8, sheds light on the question.

"This data tells us how long a patient should take Gleevec before we measure how well it's fighting the CML. This is important in helping us know when during treatment to decide if Gleevec is the best treatment or if a new approach would be better," said Brian Druker, M.D., the study's lead author. He is the JELD-WEN Chair of Leukemia Research at the OHSU Cancer Institute and an investigator of the Howard Hughes Medical Institute.

Druker studies the molecular origin of CML as a means to develop the most effective treatments. Using this approach, Druker developed Gleevec to treat CML, a malignant cancer of the bone marrow in which the body overproduces cancerous white blood cells. Gleevec targets the cancer cells while leaving normal cells unharmed, producing little or no side effects. The blood counts of virtually all CML patients treated with the drug have returned to normal.

For this study, researchers sought to determine how long Gleevec should be given to accurately gauge a patient's response. To accomplish this, they examined data from a randomized study of 553 newly diagnosed chronic phase patients comparing Gleevec, also known as imatinib, with traditional combination therapy (interferon and cytosine arabinoside).

Scientists first studied whether a CML patient's response to Gleevec is related to a patient's survival without progression of the disease. To do this, they measured the cytogenetic response, which, in this case, refers to how many bone marrow cells contain the Philadelphia chromosome. The Philadelphia c
'"/>

Contact: Rachel MacKnight
macknigh@ohsu.edu
503-494-8231
Oregon Health & Science University
6-Dec-2003


Page: 1 2 3

Related medicine news :

1. Three-year cervical cancer screening recommendations may be applicable for certain women with HIV
2. Three anti-platelet drugs used in combination are safe
3. Three out of the four million newborn babies who die each year could be saved
4. Three-year health study of teenage girls is underway at Trenton Central High School
5. Three Harvard Medical School endowed chairs named simultaneously in sleep medicine
6. Three Abbott chemists honored as Heroes for development of HIV therapy for children
7. Three Pfizer Inc chemists win Heroes award for epilepsy treatment for children, adults
8. Three Merck chemists win Heroes of Chemistry award for major asthma treatment advance
9. Three-time Emmy Award winning actress Kathy Baker to participate in ADHD experts on call program
10. Three-month antibiotic treatment reduces risk of future heart attack
11. Irritable Bowel Syndrome The Focus Of Three UNC-CH Reports At Digestive Diseases Conference

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/13/2019)... ... , ... The University of Pittsburgh School of Health and Rehabilitation Sciences (SHRS) ... degree program to address the growing need for professionals who can use data to ... effort for SHRS to bring more graduate degrees online. The Master of Science in ...
(Date:6/13/2019)... YORK (PRWEB) , ... June ... ... 3D printing—including medical and dental implants, additive manufacturing (AM)-enabled tissue fabrication, patient-matched ... day, physicians are using AM medical technologies to improve patient care. Children ...
(Date:6/12/2019)... ... June 12, 2019 , ... Recent research shows that ... patients to deteriorate. , Researchers from the University of Chichester in the ... who care for people who have dementia and experienced a declining relationship with ...
(Date:6/12/2019)... ... June 12, 2019 , ... NDA Partners ... with more than 25 years of experience in quality systems development, quality systems ... medical devices, has joined NDA Partners as an Expert Consultant. Her experience includes ...
(Date:6/12/2019)... ... ... In September of 2018, NVNA and Hospice (NVNA) partnered with Health Recovery Solutions ... full-scale launch in March, NVNA has expanded its program with HRS to provide telehealth ... achieved an average all-cause hospital readmissions rate of 7.3% and has seen a 40% ...
Breaking Medicine News(10 mins):
(Date:6/12/2019)... , ... June 12, 2019 , ... The residents of ... Blvd. and a second location at 11651 W 64th Ave. Owned by Bridget Sheils ... of CBD American Shaman products from topical creams and oils, candies and more. In ...
(Date:6/11/2019)... ... June 11, 2019 , ... The National Comprehensive ... Chemotherapy Order Templates ( NCCN Templates ®) into the CureMD Oncology EHR to ... NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). , “The collaboration with CureMD ...
(Date:6/6/2019)... ... ... MEDICC (Medical Education Cooperation with Cuba) has deplored the Trump administration’s decision ... more assault on the freedom of Americans, Cuban-Americans and the health and livelihoods of ... Directors. , MEDICC has long stood for open dialogue and cooperation with Cuban ...
Breaking Medicine Technology:
Cached News: